Maxymune Therapeutics, Inc.Amended
Biotechnology · LOS ALTOS, CA
BiotechnologySEC Form D
Maxymune Therapeutics, Inc. filed a Form D with the U.S. Securities and Exchange Commission on June 3, 2026, reporting $2,675,000 raised toward a $4,500,000 offering.
Incorporated in Delaware and based in LOS ALTOS, CA, it operates in the Biotechnology sector.
Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Maxymune Therapeutics, Inc. has raised capital from private investors.
Browse more recently funded companies in Biotechnology.
Executives & Directors
- Gordon RingoldExecutive Officer · Director
- Neil SolomonsDirector
- Tatjana NarandaExecutive Officer · Director
Recently funded in Biotechnology
Other companies that recently filed a Form D
$3.2MRaised
Goldenrod Therapeutics, Inc.
$10.0MRaised
Human Biotech, Inc.
$1.0MRaised
Optimeos Life Sciences, Inc.
$2.5MRaised
BioStem Technologies, Inc.
$10.0MRaised